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A B S T R A C T
Purpose
To determine the effect of comorbidity on prostate cancer (PCa)–specific mortality across treatment
types.
Patients and Methods
These are the results of a population-based observational study in Sweden from 1998 to 2012 of
118,543 men who were diagnosed with PCa with a median follow-up of 8.3 years (interquartile
range, 5.2 to 11.5 years) until death from PCa or other causes. Patients were categorized by patient
characteristics (marital status, educational level) and tumor characteristics (serum prostate-specific
antigen, tumor grade and clinical stage) and by treatment type (radical prostatectomy, radical ra-
diotherapy, androgen deprivation therapy, and watchful waiting). Data were stratified by Charlson
comorbidity index (0, 1, 2, or $ 3). Mortality from PCa and other causes and after stabilized inverse
probability weighting adjustments for clinical patient and tumor characteristics and treatment type
was determined. Kaplan-Meier estimates and Cox proportional hazards regression models were
used to calculate hazard ratios.
Results
In the complete unadjusted data set, we observed an effect of increased comorbidity on PCa-
specific and other-cause mortality. After adjustments for patient and tumor characteristics, the
effect of comorbidity on PCa-specific mortality was lost but maintained for other-cause mortality.
After additional adjustment for treatment type, we again failed to observe an effect for comorbidity
on PCa-specific mortality, although it was maintained for other-cause mortality.
Conclusion
This large observational study suggests that comorbidity affects other cause–mortality but not PCa-
specific– mortality after accounting for patient and tumor characteristics and treatment type. Re-
gardless of radical treatment type (radical prostatectomy or radical radiotherapy), increasing comor-
bidity does not seem to significantly affect the risk of dying from PCa. Consequently, differences in
oncologic outcomes that were observed in population-based comparative effectiveness studies of
PCa treatmentsmay not be a result of the varying distribution of comorbidity among treatment groups.
J Clin Oncol 35:3566-3574. © 2017 by American Society of Clinical Oncology. Licensed under the
Creative Commons Attribution 4.0 License: http://creativecommons.org/licenses/by/4.0/
INTRODUCTION
Prostate cancer (PCa) is one of the most common
causes of male deaths from cancer in Europe.1
Whereas watchful waiting (WW) is an accepted
method of PCa management, the risk of PCa-
specific mortality can be diminished by radical
treatment of localized tumors with either radi-
cal prostatectomy (RP)2,3 or radical radiotherapy
(RT). For non–organ-confined disease, androgen
deprivation therapy (ADT) effectively palliates
and prevents PCa-related complications, but
without a survival advantage in the absence of
combination treatment with RT for locally ad-
vanced tumors.4
Comorbidities are medical disorders that
coexist with, but are distinct from, the primary
diagnosis.5 As with PCa, comorbidity is also age
related and can influence the decision, timing,
and modality of treatment selection. Because the
survival advantage of radical therapy for PCa is
typically observed only 10 years after treatment,2
current European guidelines recommend radical
treatment with curative intent in patients with
a . 10-year life expectancy.4
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Comorbidity is highly prevalent among patients with
cancer6 and may adversely affect both competing-cause and
cancer-specific mortality,7,8 depending on the measures of
comorbidity and survival. Evidence for an effect in patients with
PCa is conflicting,1,8,9 and how comorbidity influences PCa-
specific mortality is unclear. Here, by using a population-based
observational cohort, we test the hypothesis that PCa-specific
mortality is not affected by comorbidity after accounting for
patient and tumor characteristics and treatment type.
PATIENTS AND METHODS
Study Cohort
Our study cohort is based on the Prostate Cancer Database Sweden
(PCBaSe), which is described elsewhere.10,11 In brief, PCBaSe is a com-
posite population-based data set that links the National Prostate Cancer
Register, the Swedish Cancer Register, the cause of death register, and six
other national registers by a unique personal identity number that is
assigned to every Swedish resident. PCBaSe captures more than 98% of all
cases of PCa in Sweden diagnosed since 199812 with virtually complete
data on year of diagnosis, age, clinical (TNM) stage,13 Gleason tumor
grade,14 or WHO15 tumor grade, diagnostic serum prostate-specific
antigen (PSA) levels, planned primary treatment within 6 months of
diagnosis, county of residence, marital status, educational level, so-
cioeconomic status, comorbidity, and cancer-related events during
follow-up.11 Neoadjuvant ADTwith RP was not recorded, but is a rare
management strategy; neoadjuvant ADT with RT has been recorded
since 2008 only; and information on ADT after WW was not available.
We identified a total of 129,389 men who were diagnosed with PCa
between January 1998 and December 2012 and who were observed for
survival (or death) until December 2014, which is the last date of
update for the cause of death register linkage to PCBaSe. Causes of
death were ascertained by using the cause of death register, for which
the accuracy of the data on PCa has been validated and reported to be
86%.16 After exclusion of those patients whose treatment was un-
known (n = 5,427), those who had died before treatment (n = 482), or
those who were missing one or more tumor covariates (n = 4,937) we
included all patients regardless of primary treatment or otherwise
(n = 118,543). Median follow-up time for the included cohort was 8.3
years (interquartile range, 5.2 to 11.5 years). This study was approved
by the central research ethics committee and the regional ethical
review board in Stockholm (EPN Dnr 2012/499-31/4).
Comorbidity
Comorbidity—described in PCBaSe by the Charlson comorbidity
index (CCI)17—was estimated from registrations in the Swedish National
In-Patient Register and the Swedish Cancer Register that were retrieved
from 10 years before, until the date of PCa diagnosis.9 Although outpatient
diagnoses were not included, the validity of these registers has been
demonstrated to be high for medical diagnoses18 and most cancer di-
agnoses.19 CCI is a weighted scoring system that estimates the burden of
17 groups of concomitant diseases (Data Supplement) for each patient,17
which results in four comorbidity levels that are scored from
0 (no comorbidity) to $ 3 (severe comorbidity). CCI has been previously
shown to impact treatment choices for PCa and the subsequent outcomes
of patients in PCBaSe.9
Statistical Analyses
Clinicopathologic characteristics were reported as medians and
interquartile ranges. Study end points were PCa-specific and other-cause
survival. Survival time was defined as the interval between the date of PCa
diagnosis and the date of death, emigration, or end of follow-up. When
considering one cause of death, deaths that were from a competing cause
were treated as censoring time points. Overall follow-up time was cal-
culated by using the reverse Kaplan-Meier method.20 Patients were cat-
egorized by patient factors (marital status, educational level), tumor
characteristics (PSA, clinical grade and stage), and treatment type,
namely, RP, RT, ADT, and WW. Data were stratified by CCI (0, 1, 2,
or $ 3) and treatment type as detailed in the tables and figure legends,
respectively. The x2 and Wilcoxon Mann-Whitney tests were used to
test for differences in the distributions of patient characteristics be-
tween CCI groups. To adjust for any imbalances in the distribution of
covariates among groups, we used stabilized inverse probability
weighting, a propensity score–based method for which a situation is
emulated in which the groups to be compared are made to have similar
characteristics at baseline on the basis of preselected adjustment
variables.21 For adjustments, we used patient and tumor-related
clinical characteristics that were available only at the time of treat-
ment decision, namely, age, marital status, educational level, year of
diagnosis, tumor grade, clinical stage, and PSA. Adjustment weights
were constructed by using multinomial regression wherein continuous
covariates were modeled as restricted cubic splines with three knots.
Extreme low or high weights were truncated at 0.25 and 4, respectively.
PCa-specific and other-cause survival were compared between the
actual and emulated groups by using unadjusted and weighted Kaplan-
Meier estimates and Cox proportional hazards regression models to
calculate hazard ratios. A cause-of-death–specific analysis, rather than
competing-risks analysis, was specifically used to determine whether
comorbidity affected PCa-specific or other-cause mortality under the
hypothetical scenario that no men in the overall cohort or each
treatment group (RP, RP, ADT, or WW) would die of causes other than
PCa, or from PCa, respectively.22 Statistical analyses were performed
with R software v.3.1.223 using the multinom function from the nnet
package as well as the Survival Analysis and Regression Modeling
Strategies packages. All statistical tests were two sided and performed
at a 5% significance level.
RESULTS
Baseline unadjusted patient and tumor characteristics and
treatment type (RP, RT, ADT, or WW) stratified by CCI (0, 1, 2,
or $ 3) are listed in Table 1 (the data after statistical adjustments
are listed in the Data Supplement). At diagnosis, patients with
greater comorbidity were generally older than those with no
comorbidity. Median PSA at the time of diagnosis was also higher
in the comorbid group compared with the group with no
comorbidity. Consistent with this, there was a higher proportion
of low-grade, localized tumors that were identified in the group of
patients with no comorbidity compared with the comorbid
group. Consequently, the proportion of patients who were treated
by radical therapies (RP or RT) was greater in the group of
patients with little or no comorbidity than in the more comorbid
groups in which a greater proportion of patients were treated with
ADTor WW. Of a total of 87,816 patients in CCI group 0, 16,186
patients in CCI group 1, 9,114 patients in CCI group 2, and 5,427
patients in CCI group $ 3 (Table 1) there were 15,403, 3,591,
1,895, and 1,134 PCa-related deaths and 15,203, 5,409, 3,683, and
2,849 deaths from other causes, respectively, by the end of the
study period.
In the complete unadjusted data set, we observed an effect
of increased comorbidity on PCa-specific and other-cause
mortality, which rose to a 1.99 -fold hazard (95% CI, 1.87 to
2.11) of PCa-specific mortality and a 5.62-fold hazard (95% CI,
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5.40 to 5.85) of other-cause mortality for patients with a CCI
score of $ 3 compared with those with no comorbidity (CCI 0;
Table 2 and Fig 1A, left and right panels, respectively). After
adjustments for patient and tumor characteristics, the effect of
limited comorbidity (CCI score of 1 and 2) on PCa-specific
mortality was clearly attenuated and not statistically significant,
but was maintained for other-cause mortality across all CCI
groups (Table 2 and Fig 1B, left and right panels, respectively).
After additional adjustment for treatment type, the association
between comorbidity and PCa-specific mortality was again
attenuated without clear trends across CCI groups, whereas the
effect of increasing comorbidity on other-cause mortality was
maintained (Table 2 and Fig 1C, left and right panels, re-
spectively). Of the individual comorbidities that constituted
the CCI (Data Supplement), only congestive heart failure and
dementia affected PCa-specific mortality after adjusting for
patient and tumor characteristics and treatment type (Data
Supplement).
In a subset analysis in which comparisons were repeated
separately within each treatment subgroup (Table 2 and Figs 2A-
2D, left panels), the only treatment for which an effect of
comorbidity on PCa-specific mortality was consistently ob-
served for all CCI groups compared with no comorbidity (CCI
score, 0) in unadjusted data was WW, which was lost after
adjusting for patient and tumor characteristics (Table 2). For the
RP, RT, and ADT subgroups, limited differences in PCa-specific
mortality were observed in both unadjusted and adjusted data
(Table 2). Additional analyses of a subgroup of patients who
were diagnosed and treated between 2008 and 2012 for which
information was available on neoadjuvant ADT before RT did
Table 1. Baseline Clinicopathologic and Follow-Up Data for Cohort Stratified by CCI Groups
Characteristic
All Patients
(N = 118,543)
CCI 0
(n = 87,816)
CCI 1
(n = 16,186)
CCI 2
(n = 9,114)
CCI $ 3
(n = 5,427) P
Median follow-up time, years* (IQR) 8.3 (5.2-11.5) 8.2 (5.1-11.4) 8.7 (5.3-11.8) 8.5 (5.2-11.8) 8.6 (5.0-11.9) , .001
Median year of diagnosis (IQR) 2006 (2002-2009) 2006 (2002-2009) 2005 (2002-2009) 2005 (2002-2009) 2005 (2002-2009) , .001
Median age at diagnosis (IQR) 70 (64-77) 68 (62-75) 74 (68-80) 75 (69-81) 77 (71-82) , .001
Median PSA level, ng/mL (IQR) 12.0 (6.0-31.0) 10.2 (6.0-27.0) 16.0 (8.0-44.0) 16.0 (7.6-46.0) 19.0 (8.7-55.0) , .001
Primary treatment , .001
RP 27,695 (23) 24,623 (28) 1,834 (11) 968 (11) 270 (5.0)
RT 16,262 (14) 13,143 (15) 1,920 (12) 825 (9.1) 374 (6.9)
ADT 41,785 (35) 26,690 (30) 7,646 (47) 4,360 (48) 3,089 (57)
WW 32,801 (28) 23,360 (27) 4,786, (30) 2,961 (32) 1,694 (31)
Clinical stage , .001
cT1 51,681 (44) 40,567 (46) 5,877 (36) 3,390 (37) 1,847 (34)
cT2 37,141 (31) 27,066 (31) 5,307 (33) 2,956 (32) 1,812 (33)
cT3 25,139 (21) 17,157 (20) 4,210 (26) 2,317 (25) 1,455 (27)
cT4 4,582 (3.9) 3,026 (3.4) 792 (4.9) 451 (4.9) 313 (5.8)
N stage , .001
cN0 13,375 (11) 11,004 (13) 1,316 (8.1) 725 (8.0) 330 (6.1)
cNX 102,876 (87) 75,022 (85) 14,605 (90) 8,243 (90) 5,006 (92)
cN1 2,292 (1.9) 1,790 (2.0) 265 (1.6) 146 (1.6) 91 (1.7)
M stage , .001
cM0 42,939 (36) 33,049 (38) 5,410 (33) 2,921 (32) 1,559 (29)
cMX 65,046 (55) 47,640 (54) 9,020 (56) 5,213 (57) 3,173 (58)
cM1 10,558 (8.9) 7,127 (8.1) 1,756 (11) 980 (11) 695 (13)
Gleason score or WHO stage , .001
# 6 or WHO 1 54,659 (46) 42,318 (48) 6,584 (41) 3,741 (41) 2,016 (37)
7 or WHO 2 39,608 (33) 29,030 (33) 5,637 (35) 3,078 (34) 1,863 (34)
$ 8 or WHO 3 24,276 (20) 16,468 (19) 3,965 (24) 2,295 (25) 1,548 (29)
PSA level, ng/mL , .001
0-5 18,944 (16) 15,290 (17) 1,981 (12) 1,111 (12) 562 (10)
5-10 35,739 (30) 28,390 (32) 4,007 (25) 2,224 (24) 1,118 (21)
10-20 24,110 (20) 17,670 (20) 3,428 (21) 1,850 (20) 1,162 (21)
20-50 18,505 (16) 12,505 (14) 3,069 (19) 1,803 (20) 1,128 (21)
50-100 8,477 (7.2) 5,523 (6.3) 1,511 (9.3) 866 (9.5) 577 (11)
. 100 12,768 (11) 8,438 (9.6) 2,190 (14) 1,260 (14) 880 (16)
Marital status , .001
Married 81,326 (69) 61,260 (70) 10,604 (66) 6,019 (66) 3,443 (63)
Widower 10,558 (8.9) 6,512 (7.4) 2,036 (13) 1,212 (13) 798 (15)
Divorced 15,442 (13) 11,532 (13) 2,125 (13) 1,092 (12) 693 (13)
Unmarried 11,217 (9.5) 8,512 (9.7) 1,421 (8.8) 791 (8.7) 493 (9.1)
Educational level , .001
High 25,075 (21) 20,420 (23) 2,492 (15) 1,468 (16) 695 (13)
Intermediate 43,355 (37) 32,967 (38) 5,463 (34) 3,119 (34) 1,806 (33)
Low 50,113 (42) 34,429 (39) 8,231 (51) 4,527 (50) 2,926 (54)
NOTE. Data are given as No. (%) unless otherwise indicated.
Abbreviations: ADT, androgen deprivation therapy; CCI, Charlson comorbidity index; PSA, prostate-specific antigen; RP, radical prostatectomy; RT, radical radiotherapy;
WW, watchful waiting.
*Reverse Kaplan-Meier estimate.
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not reveal any association between CCI and PCa-specific mortality
for patients who were treated with RT (Data Supplement). The most
striking effect of comorbidity on other-cause mortality was observed
in patients who were treated with RP, where patients had a 4.42-fold
hazard (95% CI, 3.23 to 6.06) in other-cause mortality with a CCI
score of $ 3 (Table 2 and Fig 2A, right panel).
Table 2. Comparison of Mortality Figures and Stabilized Inverse Probability Weighting Adjusted Subdistribution HRs for Deaths From PCa and Other Causes Between
CCI Groups, Stratified by Treatment Type
CCI Group
PCa-Specific Mortality Other-Cause Mortality
HR (95% CI) P HR (95% CI) P
All patients, unadjusted
0 1.00 [reference] 1.00 [reference]
1 1.53 (1.47 to 1.58) , .001 2.43 (2.35 to 2.50) , .001
2 1.56 (1.49 to 1.64) , .001 3.26 (3.14 to 3.38) , .001
$ 3 1.99 (1.87 to 2.11) , .001 5.62 (5.40 to 5.85) , .001
All patients, adjusted for patient and tumor characteristics
0 1.00 [reference] 1.00 [reference]
1 1.02 (0.98 to 1.06) .426 1.53 (1.48 to 1.58) , .001
2 1.03 (0.97 to 1.08) .383 2.06 (1.97 to 2.16) , .001
$ 3 1.15 (1.06 to 1.25) , .001 3.33 (3.14 to 3.54) , .001
All patients, adjusted for patient and tumor characteristics plus
treatment type
0 1.00 [reference] 1.00 [reference]
1 0.98 (0.94 to 1.02) .339 1.49 (1.43 to 1.54) , .001
2 0.98 (0.93 to 1.04) .578 1.99 (1.90 to 2.09) , .001
$ 3 1.08 (1.00 to 1.17) .066 3.16 (2.97 to 3.36) , .001
RP patients, unadjusted
0 1.00 [reference] 1.00 [reference]
1 1.15 (0.84 to 1.56) .388 1.74 (1.49 to 2.02) , .001
2 1.70 (1.19 to 2.45) .004 3.66 (3.14 to 4.27) , .001
$ 3 1.38 (0.62 to 3.08) .433 6.05 (4.78 to 7.65) , .001
RP patients, adjusted for patient and tumor characteristics
0 1.00 [reference] 1.00 [reference]
1 0.96 (0.68 to 1.35) .805 1.43 (1.21 to 1.68) , .001
2 1.27 (0.84 to 1.93) .262 2.81 (2.32 to 3.39) , .001
$ 3 1.24 (0.49 to 3.16) .654 4.42 (3.23 to 6.06) , .001
RT patients, unadjusted
0 1.00 [reference] 1.00 [reference]
1 1.07 (0.88 to 1.29) .492 1.77 (1.56 to 2.00) , .001
2 0.98 (0.73 to 1.33) .916 2.28 (1.93 to 2.68) , .001
$ 3 1.25 (0.83 to 1.90) .285 3.68 (3.02 to 4.48) , .001
RT patients, adjusted for patient and tumor characteristics
0 1.00 [reference] 1.00 [reference]
1 1.07 (0.87 to 1.30) .522 1.61 (1.42 to 1.82) , .001
2 0.98 (0.71 to 1.35) .910 2.04 (1.70 to 2.45) , .001
$ 3 1.17 (0.76 to 1.81) .463 3.23 (2.58 to 4.03) , .001
ADT patients, unadjusted
0 1.00 [reference] 1.00 [reference]
1 1.03 (0.99 to 1.08) .109 1.88 (1.80 to 1.96) , .001
2 1.03 (0.97 to 1.08) .341 2.25 (2.14 to 2.37) , .001
$ 3 1.10 (1.03 to 1.18) .004 3.41 (3.23 to 3.60) , .001
ADT patients, adjusted for patient and tumor characteristics
0 1.00 [reference] 1.00 [reference]
1 1.05 (1.01 to 1.10) .013 1.57 (1.51 to 1.65) , .001
2 1.05 (0.99 to 1.11) .126 1.91 (1.81 to 2.02) , .001
$ 3 1.10 (1.02 to 1.18) .014 2.82 (2.64 to 3.01) , .001
WW patients, unadjusted
0 1.00 [reference] 1.00 [reference]
1 1.33 (1.20 to 1.47) , .001 1.98 (1.88 to 2.09) , .001
2 1.41 (1.24 to 1.60) , .001 2.77 (2.62 to 2.94) , .001
$ 3 1.77 (1.48 to 2.10) , .001 4.78 (4.47 to 5.11) , .001
WW patients, adjusted for patient and tumor characteristics
0 1.00 [reference] 1.00 [reference]
1 0.95 (0.85 to 1.06) .332 1.50 (1.41 to 1.59) , .001
2 0.96 (0.84 to 1.10) .565 2.06 (1.92 to 2.20) , .001
$ 3 1.07 (0.87 to 1.31) .531 3.42 (3.12 to 3.74) , .001
Abbreviations: ADT, androgen deprivation therapy; CCI, Charlson comorbidity index; HR, hazard ratio; PCa, prostate cancer; PSA, prostate-specific antigen; RP, radical
prostatectomy; RT, radical radiotherapy; WW, watchful waiting.
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Fig 1. Prostate cancer (PCa)–specific (left
panels) and other-cause (right panels) sur-
vival for (A) a full cohort of patients without
adjustments, (B) a full cohort of patients
with adjustments for patient and tumor
characteristics, and (C) a full cohort of pa-
tients with adjustments for patient and tu-
mor characteristics, and treatment type.
Unadjusted and adjusted Kaplan-Meier
plots display cumulative survival proba-
bility and follow-up time . The number of
patients at risk in each Charlson comor-
bidity index (CCI) group are tabulated at
each time point on the x-axis with text
colors corresponding to the same color for
each curve on the Kaplan-Meier plot rep-
resenting CCI 0 (blue), CCI 1 (gold), CCI 2
(gray), and CCI $ 3 (red).
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Fig 2. Prostate cancer (PCa)–specific (left
panels) and other-cause (right panels) sur-
vival for a cohort of patients with adjust-
ments for patient and tumor characteristics,
stratified by treatment type. (A) Radical
prostatectomy, (B) radical radiotherapy, (C)
androgen deprivation therapy, and (D) watch-
ful waiting. Adjusted Kaplan-Meier plots
display cumulative survival probability and
follow-up time. The number of patients at
risk in each Charlson comorbidity index
(CCI) group are tabulated at each time
point on the x-axis with text colors corre-
sponding to the same color for each curve
on the Kaplan-Meier plot representing CCI
0 (blue), CCI 1 (gold), CCI 2 (gray), and CCI
$ 3 (red).
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DISCUSSION
In this large observational study of men with PCa who were treated
with RP, RT, ADT, or WW, with a maximum follow-up to 16.99
years, we did not observe a statistically significant effect of comorbidity
(as determined by CCI) on PCa-specific mortality after statistical
adjustments for patient and tumor characteristics and treatment type;
however, we did see an association with a CCI score of$ 3 compared
with no comorbidity (CCI score, 0) on PCa-specific mortality after
adjusting for patient and tumor characteristics alone, which was lost
after additional adjustments for treatment type—the reasons for this
effect are unclear. Overall, our findings suggest that, after adjusting for
patient and tumor characteristics, comorbidity does not seem to
significantly impact the risk of dying from PCa after radical
treatment (RP or RT) or WW.
Population-based studies that incorporate all disease states24-28
and a recent systematic review29 suggest that RP may be more ef-
fective than RT for the treatment of localized PCa, although
a common criticism of these analyses is that the differences observed,
at least in part, may be a result of the distribution of comorbidity
between treatment groups. The premise here is that lesser comor-
bidity in the RP group may result in residual bias that accounts for
the lower PCa-specific mortality compared with RT; however,
considering the lack of an association between comorbidity and
PCa-specific mortality for both RP and RT in our present study,
differences in oncologic outcomes that have been observed in
population-based studies may not be a result of comorbidity-
associated bias, although residual confounding is difficult to
preclude without random treatment allocation.
To date, the two largest population-based studies have re-
ported similar findings for an effect of comorbidity on other-cause
mortality, with discordant findings for an effect on PCa-specific
mortality using competing-risk models. A PCBaSe-based study
identified an association between increased comorbidity and PCa-
specific and all-cause mortality.9 A similar effect of comorbidity was
identified in all-cause, but not PCa-specific mortality in a study that
was based on the Prostate CancerOutcomes Study population-based
cohort from the National Cancer Institute SEER program.30 Consistent
with this, another large SEER-based study, which excluded all patients
who underwent radical treatment, observed similar effects of increased
comorbidity on overall survival by using a competing-risks model.31
Although the reasons for the differences in findings between the
PCBaSe 9 and SEER30 studies are unclear, possible explanations
are the patient self-reporting of comorbidity in the SEER data set30
or the misclassification of comorbidity in the PCBaSe data set.9
Other smaller studies have demonstrated an association between
increased comorbidity and risk of other cause–mortality and all
cause–mortality, but not PCa-specific mortality in men with lo-
calized PCa who were treated with RP, RT, ADT, or WW.32-34 These
studies are limited by potential bias associated with the retrospective
nature of single-center data and small numbers34 or a complete
absence of patients who were treated with ADT or WW.32,33
The above population-based studies9,30,31 that used competing-
risk models can help to determine whether the risk of death from
PCa differs between groups, allowing certain men to be protected
from PCa-specific mortality because of death from other causes. The
findings may be relevant in counseling men with comorbidity about
radical treatment options for which treatment choices are based on
shared decision-making with knowledge of the potential benefits
and harms of treatment when considering an individual’s risk of
death from PCa and/or other causes. For example, a patient with
comorbidity and a greater risk of other-cause mortality compared
with PCa-specific mortality may wish to withhold treatment to limit
PCa treatment–related morbidity without compromising oncologic
outcome. In comparison, our cause-of-death–specific analyses allow
us to emulate how comorbidity affects PCa-specific mortality under
the hypothetical scenario that nomen died of causes other than PCa.
We used this method as we wished to determine whether a patient
with comorbidity is more or less likely to die of PCa compared with
a noncomorbid patient.
Our study has several strengths. First, it utilizes a large, unique
composite population-based data set that links nine national
registries with complete data collection from the time of diagnosis
and during follow-up ofmore than 98% ofmenwhowere diagnosed
with PCa in Sweden since 1998, with well-validated patient and
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clinicopathologic variables. The accuracy of the study end point is
high, as the cause of death register in Sweden has been found to be
reliable for the correct assignment of cause of death for patients with
PCa.16 As a result of long-term follow-up, it is possible to identify
differences in mortality . 10 years after diagnosis and treatment,
thereby increasing the sensitivity of the analyses.
We used stabilized inverse probability weighting propensity
score–based statistical adjustments for preselected variables to
emulate a situation in which groups to be compared are made to
have similar characteristics at baseline; however, unmeasured or
misclassified confounders may still bias the estimates. For example,
despite the apparent validity of the cause-of-death register,16
Swedish National In-Patient Register,18 and Swedish Cancer
Register, which constitute the CCI score in PCBaSe, it is con-
ceivable that the misclassification of cause of death, or insensitivity
of comorbidity estimation, or ability to detect certain conditions
may result in bias. In addition, our PCa- and other cause–specific
survival analyses may result in bias because of informative cen-
soring if those patients who died early from other causes had at
a different risk of death from PCa than did those who survived
longer. Hence, similar analyses of large population-based PCa data
sets are needed to validate our findings.
Notwithstanding these limitations, our study suggests that
comorbidity affects other cause–mortality but not PCa-specific–
mortality, accounting for patient and tumor characteristics and
treatment type. Regardless of radical treatment type (RP or RT),
increased comorbidity does not seem to significantly affect the risk
of dying from PCa. Consequently, differences in oncologic out-
come that were observed in population-based comparative ef-
fectiveness studies of PCa treatments do not seem to be a result of
the varying distribution of comorbidity among treatment groups.
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